At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 307 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Oral Semaglutide 25 mg Once Daily in Adults With Overweight or Obesity
In Brief
A Phase 3 clinical trial evaluating Semaglutide and Placebo semaglutide for Overweight and Obesity. Completed, enrolled 307 participants across 23 sites in 4 countries.
Detailed Summary
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight, Obesity
CountriesCanada, Germany, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartOct 2022
Primary CompletionApr 2024
Study CompletionMay 2024
TodayJul 2026
First PostedOct 3, 2022
Enrollment StartOct 11, 2022
Primary CompletionApr 18, 2024
Study CompletionMay 7, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.7 years ago
Interventions
Semaglutidedrug
Semaglutide tablets orally once daily for 64 weeks.
Placebo semaglutidedrug
Semaglutide placebo-matching tablets orally once daily for 64 weeks.